Yi-Hua Zhou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1859091/publications.pdf

Version: 2024-02-01

304743 330143 1,731 93 22 37 citations h-index g-index papers 99 99 99 2330 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The optimal interval for post-vaccination serological test in infants born to mothers with positive hepatitis B surface antigen. Human Vaccines and Immunotherapeutics, 2024, 17, 5585-5589.	3.3	1
2	COVID-19 vaccination coverage among healthcare workers in obstetrics and gynecology during the first three months of vaccination campaign: a cross-sectional study in Jiangsu province, China. Human Vaccines and Immunotherapeutics, 2024, 17, 4946-4953.	3.3	6
3	Thinking More About Inhibition of Breast Milk on the Infectivity of SARS-CoV-2. JAMA Pediatrics, 2022, 176, 526.	6.2	1
4	[68Ga]Ga-PSMA-11 PET/CT has potential application in predicting tumor HIF-2α expression and therapeutic response to HIF-2α antagonists in patients with RCC. European Radiology, 2022, , .	4.5	3
5	Inhibition of In Vitro Infection of Hepatitis B Virus by Human Breastmilk. Nutrients, 2022, 14, 1561.	4.1	3
6	Identified human breast milk compositions effectively inhibit SARS-CoV-2 and variants infection and replication. IScience, 2022, 25, 104136.	4.1	17
7	Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study. Clinical Gastroenterology and Hepatology, 2022, 20, 2826-2837.e9.	4.4	6
8	Self-Reported adverse events among Chinese healthcare workers immunized with COVID-19 vaccines composed of inactivated SARS-CoV-2. Human Vaccines and Immunotherapeutics, 2022, 18, 1-7.	3.3	14
9	Efficacy of the hepatitis B vaccine alone in the prevention of hepatitis B perinatal transmission in infants born to hepatitis B e antigen-negative carrier mothers. Journal of Virus Eradication, 2022, , 100076.	0.5	5
10	Increased Protection of Earlier Use of Immunoprophylaxis in Preventing Perinatal Transmission of Hepatitis B Virus. Clinical Infectious Diseases, 2021, 73, e3317-e3323.	5.8	27
11	CSOG MFM Committee Guideline: Management of Hepatitis B During Pregnancy and Prevention of Mother-to-Child Transmission of Hepatitis B Virus (2020). Maternal-Fetal Medicine, 2021, 3, 7-17.	0.8	12
12	Evidence against in utero transmission of hepatitis B virus. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 445-445.	17.8	2
13	Reply letter regarding seroconversion of hepatitis B surface antigen in a successful long-term immune cohort. Human Vaccines and Immunotherapeutics, 2021, 17, 2775-2776.	3.3	0
14	Reduced mother-to-child transmission of hepatitis B after implementation of completely charge-free active-passive immunoprophylaxis: an observational cohort study. Expert Review of Vaccines, 2021, 20, 899-905.	4.4	9
15	Requirement for further validation on the seroconversion of hepatitis B surface antigen in successful vaccinees. Human Vaccines and Immunotherapeutics, 2021, 17, 2773-2774.	3.3	2
16	Real-World Acceptance of COVID-19 Vaccines among Healthcare Workers in Perinatal Medicine in China. Vaccines, 2021, 9, 704.	4.4	30
17	Hepatitis B Viral Markers in the Human Milk of HBsAg-Positive Mothers: An Observational Study. Journal of Human Lactation, 2021, , 089033442110430.	1.6	2
18	Metformin alleviates inflammation through suppressing FASN-dependent palmitoylation of Akt. Cell Death and Disease, 2021, 12, 934.	6.3	36

#	Article	IF	CITATIONS
19	Elimination of hepatitis B virus infection in children: experience and challenge in China. Chinese Medical Journal, 2021, 134, 2818-2824.	2.3	15
20	High mutation prevalence of precore and basal core promoter in pregnant women who underwent spontaneous HBeAg seroconversion within one year postpartum. Digestive and Liver Disease, 2020, 52, 199-204.	0.9	12
21	Insufficient Evidence to Diagnose In Utero Infection of HIV. Pediatric Infectious Disease Journal, 2020, 39, e11-e11.	2.0	1
22	The effect of whey protein on viral infection and replication of SARS-CoV-2 and pangolin coronavirus in vitro. Signal Transduction and Targeted Therapy, 2020, 5, 275.	17.1	40
23	Reply to Pan. Clinical Infectious Diseases, 2020, 73, 166-167.	5.8	1
24	Importance of timely management of patients in reducing fatality rate of coronavirus disease 2019. Journal of Infection and Public Health, 2020, 13, 890-892.	4.1	16
25	Comparison of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and multi-parametric magnetic resonance imaging (MRI) in the evaluation of tumor extension of primary prostate cancer. Translational Andrology and Urology, 2020. 9. 382-390.	1.4	26
26	Occult hepatitis B infection in vaccinated children with negative antiâ€HBc, true or not?. Liver International, 2020, 40, 2570-2570.	3.9	1
27	Is novel coronavirus disease (COVIDâ€19) transmitted through conjunctiva?. Journal of Medical Virology, 2020, 92, 1408-1409.	5.0	54
28	Hepatitis B vaccine development and implementation. Human Vaccines and Immunotherapeutics, 2020, 16, 1533-1544.	3.3	45
29	Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus ($\langle scp \rangle COVID \langle scp \rangle \hat{a} \in \mathbb{R}^9$) infection. International Journal of Gynecology and Obstetrics, 2020, 149, 130-136.	2.3	215
30	Overview of infection causing hepatitis other than non-A to E hepatitis virus during pregnancy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 68, 89-102.	2.8	6
31	Diagnosis of HIV infection in breastfed infants of mothers on antiretroviral therapy. Aids, 2020, 34, 797.	2.2	0
32	Conservative Evolution of Hepatitis B Virus Precore and Core Gene During Immune Tolerant Phase in Intrafamilial Transmission. Virologica Sinica, 2020, 35, 388-397.	3.0	5
33	Thinking more about therapy with convalescent plasma for COVID-19 patients. Human Vaccines and Immunotherapeutics, 2020, 16, 2601-2603.	3.3	2
34	Optimal Management in Preventing Mother-to-Infant Transmission of Hepatitis B: More Requires to Be Done. Clinical Gastroenterology and Hepatology, 2020, 18, 755-756.	4.4	2
35	Possibly critical role of wearing masks in general population in controlling COVIDâ€19. Journal of Medical Virology, 2020, 92, 1779-1781.	5.0	11
36	Comment on "Placental infection of hepatitis B virus among Thai pregnant women: Clinical risk factors and its association with fetal infection― Prenatal Diagnosis, 2020, 40, 1612-1613.	2.3	0

#	Article	IF	Citations
37	Prevention of Mother-to-Child Transmission of HIV: Data Analysis Based on Pregnant Women Population from 2012 to 2018, in Nantong City, China. Current HIV Research, 2020, 18, 458-465.	0.5	О
38	Comment on "Motherâ€ŧo hild transmission of hepatitis B virus after amniocentesis: A retrospective matched cohort study― Prenatal Diagnosis, 2019, 39, 1298-1299.	2.3	0
39	Dynamic changes of lymphocyte counts in adult patients with severe pandemic H1N1 influenza A. Journal of Infection and Public Health, 2019, 12, 878-883.	4.1	42
40	Is hepatitis B antigen in cord blood an immunotolerogen playing a critical role in the pathogenesis of chronic hepatitis B?. Human Vaccines and Immunotherapeutics, 2019, 15, 2192-2194.	3.3	0
41	Maternal immunisation and neonatal infection of hepatitis A or B virus. Lancet Infectious Diseases, The, 2019, 19, 238.	9.1	O
42	Comparison of antibody response to hepatitis B vaccination in infants with positive or negative maternal hepatitis B e antigen (HBeAg) in cord blood: implication for the role of HBeAg as an immunotolerogen. Human Vaccines and Immunotherapeutics, 2019, 15, 2183-2186.	3.3	8
43	Issues Meriting Further Study in Preventing Mother-to-Infant Transmission of Hepatitis B by Antiviral Therapy During Pregnancy. Maternal-Fetal Medicine, 2019, 1, 43-47.	0.8	10
44	Unnecessary to Extend Postpartum Antiviral Therapy in Pregnant Women With High Hepatitis B Viral Loads. Journal of Clinical Gastroenterology, 2019, 53, 473-474.	2.2	0
45	Presence of hepatitis B virus markers in umbilical cord blood: Exposure to or infection with the virus?. Digestive and Liver Disease, 2019, 51, 864-869.	0.9	29
46	Revaccination against hepatitis B in late teenagers who received vaccination during infancy: Yes or no?. Human Vaccines and Immunotherapeutics, 2018, 14, 456-463.	3.3	16
47	Safety and efficacy of telbivudine in late pregnancy to prevent motherâ€toâ€child transmission of hepatitis B virus: A multicenter prospective cohort study. Journal of Viral Hepatitis, 2018, 25, 429-437.	2.0	57
48	Be cautious for exceptional results in evaluating the effect of adolescent booster of hepatitis B vaccine. International Journal of Infectious Diseases, 2018, 66, 150-152.	3.3	4
49	Treatment of Chronic Hepatitis B Infection. JAMA - Journal of the American Medical Association, 2018, 320, 1201.	7.4	4
50	Be cautious in comparing the seroprevalence of hepatitis E detected at different years in different countries. Liver International, 2018, 38, 2340-2340.	3.9	2
51	Comparison of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient. Virus Research, 2018, 255, 165-170.	2.2	8
52	Comparison of hepatitis B viral loads and viral antigen levels in child-bearing age women with and without pregnancy. BMC Pregnancy and Childbirth, 2018, 18, 292.	2.4	12
53	Global prevalence of hepatitis B virus infection and prevention of mother-to-child transmission. The Lancet Gastroenterology and Hepatology, 2018, 3, 598.	8.1	6
54	Congenital biliary atresia in an infant born to hepatitis B mother treated with telbivudine before and during pregnancy. Digestive and Liver Disease, 2018, 50, 1097-1098.	0.9	5

#	Article	IF	CITATIONS
55	Is revaccination required in children who received a full primary vaccination against hepatitis B in infancy? A letter in response to Changes and analysis of antiâ∈HBs titres after primary immunization in 1â€to 16â€yearâ€old Chinese children: A hospitalâ€based study. Journal of Viral Hepatitis, 2018, 25, 1220-1220.	2.0	0
56	Minimal association of alleles of human leukocyte antigen class II gene and long-term antibody response to hepatitis B vaccine vaccinated during infancy. Vaccine, 2017, 35, 2457-2462.	3.8	13
57	RE: Fine Particle Pollution, Alanine Transaminase, and Liver Cancer: A Taiwanese Prospective Cohort Study (REVEAL-HBV). Journal of the National Cancer Institute, 2017, 109, djw184.	6.3	2
58	Clinical and Virological Characteristics of Chronic Hepatitis B Patients with Coexistence of HBsAg and Anti-HBs. PLoS ONE, 2016, 11, e0146980.	2.5	12
59	Occult hepatitis B virus infection, or occult crossâ€contamination, in children of HBsAgâ€positive mothers. Journal of Viral Hepatitis, 2016, 23, 830-830.	2.0	6
60	Prevention of motherâ€toâ€child transmission of hepatitis B virus by treating mothers with high viral loads. Hepatology, 2016, 64, 1823-1824.	7.3	5
61	Minimization of hepatitis B infection among children in Jiangsu, China, 12 years after integration of hepatitis B vaccine into the expanded program on immunization. Vaccine, 2016, 34, 6458-6463.	3.8	16
62	Changing hepatitis B virus epidemiology in rural China. Lancet Infectious Diseases, The, 2016, 16, 150-151.	9.1	1
63	Immunobiology and Host Response to HEV. Advances in Experimental Medicine and Biology, 2016, 948, 113-141.	1.6	5
64	Incidence and seroprevalence of hepatitis E virus infection in pregnant women infected with hepatitis B virus and antibody placental transfer in infants. Journal of Clinical Virology, 2016, 82, 84-88.	3.1	6
65	Virological Determinants of Spontaneous Postpartum e Antigen Seroconversion and Surface Antigen Seroclearance in Pregnant Women Infected with Hepatitis B Virus. Archives of Medical Research, 2016, 47, 207-213.	3.3	12
66	Rare detection of cytomegalovirus in severe fetal malformations in China. Journal of Clinical Virology, 2016, 79, 54-60.	3.1	5
67	Hepatitis E virus seroprevalence in pregnant women in Jiangsu, China, and postpartum evolution during six years. BMC Infectious Diseases, 2015, 15, 560.	2.9	21
68	Kinetic Changes of Viremia and Viral Antigens of Hepatitis B Virus During and After Pregnancy. Medicine (United States), 2015, 94, e2001.	1.0	18
69	Minimal adverse influence of maternal hepatitis B carrier status on perinatal outcomes and child's growth. Journal of Maternal-Fetal and Neonatal Medicine, 2015, 28, 2192-2196.	1.5	20
70	Occult hepatitis B virus infection with positive hepatitis B e antigen. Clinica Chimica Acta, 2015, 438, 266-268.	1.1	8
71	Cytomegalovirus Seroprevalence in Pregnant Women and Association with Adverse Pregnancy/Neonatal Outcomes in Jiangsu Province, China. PLoS ONE, 2014, 9, e107645.	2.5	23
72	Adefovir as a possible teratogen: Evidence from paternal exposure. Digestive and Liver Disease, 2014, 46, 1134-1135.	0.9	3

#	Article	IF	CITATIONS
73	Profiles of Acute Cytokine and Antibody Responses in Patients Infected with Avian Influenza A H7N9. PLoS ONE, 2014, 9, e101788.	2.5	20
74	Rare Detection of Occult Hepatitis B Virus Infection in Children of Mothers with Positive Hepatitis B Surface Antigen. PLoS ONE, 2014, 9, e112803.	2.5	10
75	Effect of elective cesarean section on the risk of mother-to-child transmission of hepatitis B virus. BMC Pregnancy and Childbirth, 2013, 13, 119.	2.4	41
76	Breastfeeding Is Not a Risk Factor for Mother-to-Child Transmission of Hepatitis B Virus. PLoS ONE, 2013, 8, e55303.	2.5	54
77	A knowledge survey of obstetrics and gynecology staff on the prevention of mother-to-child transmission of hepatitis B virus. Journal of Infection in Developing Countries, 2013, 7, 391-397.	1.2	11
78	Avian Influenza A(H7N9) Virus Screening in Patients with Fever and Flu-Like Symptoms in a Tertiary Hospital in an Area with Confirmed Cases. PLoS ONE, 2013, 8, e82613.	2.5	3
79	Association of polymorphisms of cytokine and TLR-2 genes with long-term immunity to hepatitis B in children vaccinated early in life. Vaccine, 2012, 30, 5708-5713.	3.8	34
80	Gaps in the prevention of perinatal transmission of hepatitis B virus between recommendations and routine practices in a highly endemic region: a provincial population-based study in China. BMC Infectious Diseases, 2012, 12, 221.	2.9	45
81	Kinetics of IgG antibody to cytomegalovirus (CMV) after birth and seroprevalence of anti-CMV IgG in Chinese children. Virology Journal, 2012, 9, 304.	3.4	32
82	Transplacentally Acquired Maternal Antibody against Hepatitis B Surface Antigen in Infants and its Influence on the Response to Hepatitis B Vaccine. PLoS ONE, 2011, 6, e25130.	2.5	23
83	Application of Truncated Immunodominant Polypeptide from Hepatitis E Virus (HEV) ORF2 in an Assay To Exclude Nonspecific Binding in Detecting Anti-HEV Immunoglobulin M. Journal of Clinical Microbiology, 2010, 48, 779-784.	3.9	13
84	Monitoring human cytomegalovirus infection with nested PCR: comparison of positive rates in plasma and leukocytes and with quantitative PCR. Virology Journal, 2010, 7, 73.	3.4	19
85	Seroprevalence of hepatitis B surface antigen among pregnant women in Jiangsu, China, 17 years after introduction of hepatitis B vaccine. International Journal of Gynecology and Obstetrics, 2010, 109, 194-197.	2.3	46
86	Non-reproducible results in genetic association studies in chronic hepatitis B due to the inadequate controls. Chinese Medical Journal, 2010, 123, 2475-7.	2.3	0
87	A novel hepatitis B virus mutant coexisting with wild type virus in a carrier with negative HBsAg yet positive HBeAg and anti-HBs. Journal of Clinical Virology, 2009, 46, 363-366.	3.1	9
88	Triptolide promotes generation of FoxP3+ T regulatory cells in rats. Journal of Ethnopharmacology, 2009, 125, 41-46.	4.1	16
89	Vaccination against hepatitis B: the Chinese experience. Chinese Medical Journal, 2009, 122, 98-102.	2.3	54
90	Influence of maternal antibody against hepatitis B surface antigen on active immune response to hepatitis B vaccine in infants. Vaccine, 2008, 26, 6064-6067.	3.8	35

Yı-Hua Zhou

#	Article	IF	CITATIONS
91	Mutations within Potential Glycosylation Sites in the Capsid Protein of Hepatitis E Virus Prevent the Formation of Infectious Virus Particles. Journal of Virology, 2008, 82, 1185-1194.	3.4	100
92	A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus. Vaccine, 2005, 23, 3157-3165.	3.8	60
93	An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes $1, 2, 3$, and 4 . Vaccine, $2004, 22, 2578-2585$.	3.8	89